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Strengths and limitations of this study
 ► This review is the first to synthesise the existing 
evidence on multimorbidity in patients with chronic 
kidney disease and it included a range of settings.
 ► The outcomes of interest were chosen by research-
ers and these do not include all outcomes that are 
important to patients, for example, quality of life.
 ► Two authors independently performed paper selec-
tion, data extraction and quality appraisal.
 ► Meta- analysis was performed, but only included se-
lected papers because of methodological heteroge-
neity of papers.
AbStrACt
Objective To systematically review the literature exploring 
the associations between multimorbidity (the presence 
of two or more long- term conditions (LTCs)) and adverse 
clinical outcomes in patients with chronic kidney disease 
(CKD).
Design Systematic review and meta- analysis.
Data sources MEDLINE, EMBASE, CINAHL, Cochrane 
Library and SCOPUS (1946–2019). The main search terms 
were ‘Chronic Kidney Failure’ and ‘Multimorbid*’.
Eligibility criteria Observational studies of adults over 
the age of 18 with CKD stages 3–5, that is, estimated 
glomerular filtration rate less than 60 mL/min/1.73 m2. The 
exposure was multimorbidity quantified by measures and 
the outcomes were all- cause mortality, renal progression, 
hospitalisation and cardiovascular events. We did not 
consider CKD as a comorbid LTC.
Data extraction and synthesis Newcastle- Ottawa Scale 
for quality appraisal and risk of bias assessment and fixed 
effects meta- analysis for data synthesis.
results Of 1852 papers identified, 26 met the inclusion 
criteria. 21 papers involved patients with advanced CKD 
and no studies were from low or middle- income countries. 
All- cause mortality was an outcome in all studies. Patients 
with multimorbidity were at higher risk of mortality 
compared with patients without multimorbidity (total risk 
ratio 2.28 (95% CI 1.81 to 2.88)). The risk of mortality 
was higher with increasing multimorbidity (total HR 1.31 
(95% CI 1.27 to 1.36)) and both concordant and discordant 
LTCs were associated with heightened risk. Multimorbidity 
was associated with renal progression in four studies, 
hospitalisation in five studies and cardiovascular events in 
two studies.
Limitations Meta- analysis could only include 10 
of 26 papers as the methodologies of studies were 
heterogeneous.
Conclusions There are associations between 
multimorbidity and adverse clinical outcomes in patients 
with CKD. However, most data relate to mortality risk in 
patients with advanced CKD. There is limited evidence 
regarding patients with mild to moderate CKD, outcomes 
such as cardiovascular events, types of LTCs and regarding 
patients from low or middle- income countries.
PrOSPErO registration number CRD42019147424.
IntrODuCtIOn
Multimorbidity is the presence of two or 
more long- term conditions (LTC).1 In a Scot-
tish study of 1.8 million patients, it was found 
to affect 23% of the whole population and in 
particular those from areas of lower socioeco-
nomic status.2 It is a problem for individual 
patients because it is associated with complex 
treatment regimens that result in a high 
burden of treatment and reduced quality of 
life.3 For clinicians and health services, caring 
for these individuals represents a huge work-
load and equates to approximately two- thirds 
of healthcare spending.4 The current disease- 
orientated approaches of guidelines and 
healthcare are inadequate for patients with 
multiple LTCs and complex needs.5
Multimorbidity is more common in 
patients with chronic kidney disease (CKD) 
than any other LTC: for example, among 
2.5 million Canadians, patients with CKD had 
more comorbid LTCs than patients with lung 
disease (mean 4.2 LTCs vs 2.8).6 The preva-
lence of CKD is around 12%7 and as this rises 
globally, the adverse effects of CKD and multi-
morbidity on quality of life are increasing.8 
The leading cause of death in patients with 
CKD is cardiovascular disease and although 
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this is partly related to risk factors common to both condi-
tions, low estimated glomerular filtration rate (eGFR) and 
proteinuria are predictors of cardiovascular mortality.9 10 
The higher cardiovascular risk observed among patients 
with CKD is independent of traditional atherosclerotic 
risk factors such as hypertension and dyslipidaemia, but 
the reasons for this and the influence of multimorbidity 
on CKD are incompletely understood. CKD and multi-
morbidity therefore occur together frequently and there 
are a number of issues common to both problems such as 
polypharmacy and significant treatment burden.11
We undertook this systematic review to establish the 
current evidence concerning associations between multi-
morbidity and adverse clinical outcomes in patients with 
CKD.
MAtErIALS AnD MEthODS
The Preferred Reporting Items for Systematic Review and 
Meta- Analysis Protocols guidelines were followed12 and 
this review was registered with the International Prospec-
tive Register of Systematic Reviews.
Literature search
A comprehensive search strategy identified studies of 
patients with CKD that investigated the associations 
between multimorbidity and adverse clinical outcomes 
(see online supplementary file 1 for search terms). We 
included observational studies; in particular those using 
electronic healthcare records. There was no restriction 
on sample size. The databases searched included studies 
from 1946 to 2019. The search was limited to papers 
published in English. Databases searched were MEDLINE 
(OVID interface), EMBASE (OVID interface), CINAHL 
Complete (EBSCO interface), the Cochrane Library 
(OVID interface) and SCOPUS. Selected Medical Subject 
Headings were combined with keywords relating to multi-
morbidity and CKD to create a search strategy which was 
produced for use in MEDLINE and amended for use in 
the other databases, using controlled vocabulary, Boolean 
operators and search symbols. The search was carried out 
to include literature published up to 29 August 2019. The 
results were supplemented with searches of reference lists 
of included studies. Search data were stored and merged 
using Endnote X9 (Clarivate Analytics, Philadelphia, 
USA) and papers were shared and assessed using Distill-
erSR (Evidence Partners, Ottawa, Canada).
Inclusion criteria
We included empirical quantitative studies that contained 
data on associations between multimorbidity measures 
and all- cause mortality or additional outcomes in adults 
with CKD. We accepted any multimorbidity measure, 
which included simple counts of LTCs and comor-
bidity scoring systems. We did not consider CKD as a 
comorbid LTC because all of the patients in our papers 
had CKD. Additional outcomes were hospitalisation, 
cardiovascular events, cardiovascular deaths, heart failure 
hospitalisations and renal progression (40% reduction in 
eGFR, doubling of serum creatinine or initiation of renal 
replacement therapy (RRT)). Studies that analysed the 
relationship between a multimorbidity measure and any 
of our outcomes of interest were included in adults over 
the age of 18 with CKD stages 3–5, that is, eGFR less than 
60 mL/min/1.73 m2 including those requiring RRT, that 
is, haemodialysis (HD), peritoneal dialysis (PD) or renal 
transplantation.
Exclusion criteria
Review articles, drug intervention studies, qualitative 
studies, case reports and conference abstracts were 
excluded. Studies with children or adolescents aged 18 
or under, animals and individuals without CKD were 
excluded.
The study selection process was conducted by two 
reviewers (MS, AR). Title screening was followed by 
abstract and full paper review, where necessary. Any inter- 
reviewer disagreements were resolved by a third reviewer 
(PM).
Data extraction
As recommended by the Cochrane Handbook,13 data 
were extracted in a Population, Exposure, Comparator, 
Outcomes approach:
Population: We extracted data on the characteristics of 
study populations: country, sample size, follow- up time 
and setting, that is, CKD, HD, PD, renal transplant and 
conservative care.
Exposure: We extracted the multimorbidity measure 
used in each study and whether LTCs were categorised 
into different types for analysis.
Comparator: We extracted the details provided of 
comparator groups, that is, patients with CKD with less 
than two LTCs. We did not count CKD as an LTC.
Outcomes: We extracted details of the statistical anal-
yses employed to evaluate the relationship between multi-
morbidity measure and outcomes. Risks were expressed 
as effect sizes with 95% confidence intervals (CIs), where 
available.
Data synthesis and analysis
Results were presented in a narrative format. Where 
possible, fixed effects meta- analysis was performed for 
the primary outcome, all- cause mortality. Previous system-
atic reviews including patients from the general popula-
tion have demonstrated consistent associations between 
multimorbidity and mortality.14 We assumed the direc-
tion of effect of multimorbidity on mortality would be 
consistent across our studies, barring sampling errors 
and differences in sample size, and so we applied fixed 
effects models. However, random effects models were also 
performed as sensitivity analysis, as this approach would 
be more helpful if the participants in the included studies 
were inherently different. The generic inverse variance 
method was used where multimorbidity was expressed as a 
continuous variable and the Mantel- Haenszel method was 
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Figure 1 Preferred Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA) flow diagram.
used where multimorbidity was expressed as a categorical 
variable. Quantification of statistical heterogeneity was 
assessed by means of I2, which shows the percentage of 
total variation across studies due to heterogeneity.13 These 
analyses were carried out using RevMan V.5.3 (Cochrane 
Collaboration, Copenhagen, Denmark). Meta- analysis 
was limited by heterogeneous methodologies: variable 
multimorbidity measures, use of effect sizes (hazard ratios 
(HRs), risk ratios (RR), Kaplan- Meier curves) and the use 
of multimorbidity as a continuous and categorical vari-
able. We therefore performed meta- analysis where several 
studies used similar methodologies. Data on numbers of 
deceased patients were not available for all studies and 
so we contacted study authors for their primary data. For 
meta- analysis and where necessary and possible, we calcu-
lated RRs for studies, comparing patients with multimor-
bidity to those without multimorbidity. HRs could not be 
calculated as there were no individual time- to- event data.
Quality appraisal
Two researchers conducted quality appraisal inde-
pendently (MS, AR). Studies were assessed using an 
adapted Newcastle- Ottawa Scale (NOS) for quality assess-
ment, as informed by the Cochrane Handbook13 (see 
online supplementary file 2). Studies were not excluded 
based on quality appraisal.
Patient and public involvement
No patients were involved.
rESuLtS
Search results
Figure 1 demonstrates the literature search flow. After 
the removal of duplicate papers, 1852 papers were iden-
tified. A total of 1756 papers were excluded as they were 
not relevant and so 96 full papers were screened and 26 
papers met our eligibility criteria and were included in 
the review.15–40
Study characteristics
Table 1 lists the characteristics of the 26 included studies. 
The studies were published between 1995 and 2019 and 
all used a cohort design. The size of populations was 
between 69 and 821 334. Fourteen studies examined the 
subjects predominantly on dialysis15 17–22 25 27 30 33 35 40; five 
included patients with CKD stages 3–516 24 34 36 including 
two with mild CKD24 34; two involved patients with CKD 
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  Beddhu et al15 USA HD/PD 268 13.1 ✔ Hospitalisation
  Chae et al17 South Korea HD 456 40.6 ✔   
  Chandna et al19 UK HD/PD 292 63 ✔ Hospitalisation
  Chandna et al18 UK CC/RRT 844 58.7* ✔   
  Davies et al21 UK PD 97 30 ✔   
  Davies et al20 UK PD 303 72.0* ✔   
  Di Iorio et al 22 Italy HD 515 15 ✔   
  Fried et al 25 USA PD 268 16.9 ✔   
  Hemmelgarn et al 27 Canada HD/PD 237 26.3 ✔   
  Park et al 30 South Korea HD 24 738 47.7 ✔   
  Rattanasompattikul et 
al33
USA HD 893 72 ✔   
  Shum et al35 China PD/CC 157 23.5 ✔ Hospitalisation
  van Manen et al37 Netherlands HD/PD 589 NK ✔   
  Wu et al40 Taiwan HD/PD 79 645 NK ✔   
Non- RRT CKD
  Bowling et al16 USA CKD 3–5 821 334 81.6 ✔   
  Fraser et al24 UK CKD 3 1741 43.2 ✔   
  Lee et al28 Taiwan CKD 3–5 1463 76.7 ✔ Renal progression
  Lhotta et al29 Austria CKD 5 75 48 ✔   
  Ritchie et al34 USA CKD/heart 
failure
1974 32.6 ✔ Hospitalisation, HF 
hospitalisation, CV 
death




  Pérez Fernández et al31 USA Tx 
assessment
2086 NK ✔   
  Grosso et al26 Italy Tx recipients 223 NK ✔ Renal progression
  Pieloch et al32 USA Tx recipients 100 261 36 ✔ Renal progression
  Wu et al39 USA Tx recipients 715 40.2 ✔ Renal progression
Conservative care
  Ellam et al23 UK CC 69 21* ✔   
  Wong et al38 UK CC 73 23.4* ✔   
*Median survival.
CC, conservative care; CKD, chronic kidney disease; CV, cardiovascular; HD, haemodialysis; HF, heart failure; NK, not known; PD, peritoneal 
dialysis; RRT, renal replacement therapy; Tx, transplant.
stage 5 including those not on RRT or conservative 
care29 31; two included those receiving conservative 
care23 38; three included renal transplant recipients.26 32 39
Table 2 shows the number of studies using each multi-
morbidity measure and how the corresponding effect sizes 
were presented: as a categorical or a continuous variable. 
In addition to these, three studies examined more than 
one multimorbidity measure: comparing how effectively 
each measure predicted outcomes.22 27 37 Ten studies 
used the Charlson Comorbidity Index (CCI) or a modi-
fication of this scale (modified CCI).15 17 25 26 30 31 33 35 39 40 
Seven studies used the number of LTCs, that is, condition 
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Table 2 Studies using each multimorbidity measure
Variable type
Multimorbidity measure: number of studies
CCI Condition count CSS KTMI
Heart failure and CKD versus
heart failure, CKD and diabetes
Categorical 6 4 1 1 1
Continuous 6 4 1 0 0
CCI, Charlson Comorbidity Index; CKD, chronic kidney disease; CSS, comorbidity severity score; KTMI, Kidney Transplant Morbidity Index.
count.16 23 24 28 29 36 38 Two studies used the Stoke comor-
bidity grade, which uses condition count to divide 
patients into low, intermediate and high grades.20 21 Two 
studies used the comorbidity severity score.18 19 One study 
compared those with CKD, diabetes and heart failure to 
those with just CKD and heart failure.34 One study used 
the Kidney Transplant Morbidity Index.32
All studies reported the effect of multimorbidity on 
all- cause mortality. Five studies reported the effect of 
multimorbidity on hospitalisation15 19 34 35 35 36 and four on 
renal progression.26 28 32 39 One study reported the effect 
of multimorbidity on heart failure hospitalisation and 
cardiovascular death34 and one study reported the effect 
of multimorbidity on myocardial infarction.36 Twelve 
studies expressed effect sizes using multimorbidity as a 
categorical variable,16–18 24 26 28 32–34 36 39 40 nine as a contin-
uous variable15 19–21 25 29 30 35 38 and one as both.31 One 
study gave a narrative comparison of groups23 and two 
used Kaplan- Meier curves.27 37 Two studies categorised 
LTCs into types: both used concordant and discordant as 
types and one also specified mental health and chronic 
pain LTCs.16 36
Main findings
The results of the included studies were summarised in 
online supplementary file 3. Some papers did not provide 
adjusted HRs. To make it easier to compare the studies, 
we therefore quoted unadjusted HRs. Where multimor-
bidity was used as a categorical variable, 12 of 13 studies 
found that patients with multimorbidity had higher rates 
of mortality than patients without multimorbidity. In 
the one study that did not detect a difference, Lee et al’s 
primary outcome was renal progression.28 For all- cause 
mortality, the authors provided event rates and Kaplan- 
Meier curves but there were no HRs with adjustments for 
confounding variables.
Where multimorbidity was used as a continuous vari-
able, 10 of 11 studies found that with each increase in 
multimorbidity measure, all- cause mortality was higher. 
In the one study to not detect a difference, Ellam et al was 
a study of just 69 conservatively managed patients.23
Of the four studies that reported renal progression, 
three were in renal transplant recipients.26 31 32 All four 
studies demonstrated higher rates of renal progression in 
patients with multimorbidity (HRs from each study 2.97 
(95% CI 1.53 to 5.76), 2.44 (95% CI 1.19 to 5.02), 3.11 
(95% CI 2.55 to 3.80), 1.42 (95% CI 1.02 to 1.97)). Renal 
progression was defined by graft loss or RRT initiation 
and one paper reported significant annual reductions 
in eGFR by increasing number of LTCs.28 Five studies 
reported rates of hospitalisation and all of these identi-
fied an association between multimorbidity and hospital-
isation.15 19 34–36
One paper reported rates of heart failure hospitalisa-
tion and cardiovascular death34: patients with multimor-
bidity had higher rates of both outcomes than patients 
without multimorbidity. One paper reported higher rates 
of myocardial infarction in patients with multimorbidity.36
Two papers described the influence of concordant and 
discordant LTCs on adverse outcomes.16 36 These papers 
found that both types of LTC were associated with higher 
rates of mortality. One paper found that the rates of 
outcomes were higher in patients with at least one discor-
dant LTC compared with patients with only concordant 
LTCs.16 No association was identified between mental 
health and chronic pain LTCs and myocardial infarction.36
Meta-analysis
Data synthesis was problematic because each study 
reported different effect sizes for different categorical 
groups. We therefore performed meta- analysis for all- 
cause mortality where several studies used comparable 
methodologies. Figure 2 included studies that used CCI 
as a continuous variable, demonstrating that with each 
increase in CCI, the risk of mortality was higher (total 
HR 1.31 (95% CI 1.27 to 1.36)). All studies included in 
this meta- analysis had HRs available. Figure 3 included 
studies that used condition count as a categorical vari-
able: demonstrating that patients with multimorbidity 
were at higher risk of mortality compared with patients 
without multimorbidity (total RR 2.28 (95% CI 1.81 to 
2.88)). RR was used here because time- to- event data were 
not available for all these studies and so HRs could not 
be calculated. There was considerable statistical heteroge-
neity in the studies included in each meta- analysis (I2 97% 
in figure 2 and 78% in figure 3). Subgroup analyses were 
not possible such as for patients with mild to moderate 
CKD because there were inadequate studies. Where 
random effects models were fitted, there remained signif-
icant associations between multimorbidity and all- cause 
mortality (online supplementary file 4). For studies that 
used CCI as a continuous variable, the risk of mortality 
was higher for each increase in CCI (total HR 1.37 (95% 
CI 1.07 to 1.75)). For studies that used condition count as 
a categorical variable, patients with multimorbidity were 
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Figure 2 Mortality risk for each increase in Charlson Comorbidity Index (generic inverse variance method, fixed effects model).
Figure 3 Mortality risk for patients with multimorbidity (Mantel- Haenszel method, fixed effects model).
at higher risk of mortality compared with patients without 
multimorbidity (total RR 2.53 (95% CI 1.57 to 4.07)).
risk of bias
All studies selected patients with and without multi-
morbidity from the same cohort and used either secure 
medical records or structured interviews to collect data. 
Most studies included just one group of patients with 
CKD such as patients receiving HD and only three studies 
included patients with a true range of mild to severe 
CKD.16 28 36 All but two studies controlled for factors such 
as ischaemic heart disease, age or diabetes.18 23 Only one 
study made a statement about subjects who were lost to 
follow- up.27 However, as all the studies were based on 
healthcare databases, it is reasonable to assume complete 
or near- complete follow- up. All studies followed up 
patients for more than 1 year, but there was variation in the 
average length of follow- up (from 13.1 to 81.6 months). 
Four studies did not specify the average follow- up time 
but from their survival analyses, it was clear that patients 
were followed up for at least 1 year.26 31 37 40
The NOS score evaluation of each study was between 
five and seven stars (see online supplementary file 5). The 
two studies that did not control for confounding factors 
were ‘poor’ quality as per the Agency for Healthcare 
Research and Quality standards.18 23 41 The remainder 
were ‘good’ quality.15–17 19–22 24–40
DISCuSSIOn
To the best of our knowledge, this is the first system-
atic review and meta- analysis to synthesise the existing 
evidence on the associations between multimorbidity and 
outcomes specific to patients with CKD. It is increasingly 
recognised that multimorbidity and the management of 
patients with disease clusters are challenging problems.42 
The medical profession has been given a mandate to 
improve the care of patients affected by multimorbidity 
and to do so, improving our understanding of the issues 
will be fundamental. Multimorbidity has been studied in 
the general population, with clear associations reported 
between it and high rates of mortality.43 It is time for 
researchers to build a body of evidence about patients with 
kidney disease. Our review demonstrates that for patients 
with CKD, multimorbidity is associated with high rates of 
mortality, and the risk is higher with increasing numbers 
of LTCs. Unfortunately, the literature provides little detail 
beyond this association. Of the papers in the review, only 
two categorised LTCs and studied whether the type of 
LTCs influenced outcomes. Tonelli et al and Bowling et al 
found that concordant LTCs such as diabetes were associ-
ated with high rates of mortality, but so were discordant or 
unrelated LTCs like cancer and depression.16 36 Bowling 
et al found that the presence of one or more discordant 
LTCs conferred higher risk compared with patients with 
only concordant LTCs. This suggests that there are groups 
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of patients in whom it is the number and the type of LTCs 
that put them at elevated risk. Further research is needed 
into what patterns or clusters of disease exist to help clini-
cians understand the risks faced by patients with CKD and 
multimorbidity.
Patients require clinicians to help with their overall 
health and quality of life, not just the status of indi-
vidual LTCs. As seen in the Standardized Outcomes in 
Nephrology- Hemodialysis initiative, patients usually 
wish to understand the risks they face. However, there 
is often a mismatch between the outcomes regarded as 
important by patients to those emphasised in clinical 
guidelines.44 45 It is therefore imperative that we consider 
patient- oriented outcomes when studying multimorbidity 
and ensure that research leads to improvements in care 
for patients. A limitation of our review is that we did not 
summarise outcomes prioritised by patients. The merit in 
investigating multimorbidity in patients with CKD will be 
that patients and clinicians will have an improved under-
standing of the risks they face. They will therefore be able 
to prioritise particular interventions such as cardiovas-
cular risk factor modification and vascular access creation.
Despite the methodological and clinical heterogeneity 
of the studies in our review, the findings are consistent 
with existing literature.11 We have confirmed associations 
between multimorbidity and adverse clinical outcomes in 
RRT and non- RRT settings, and in a range of countries. 
Twenty- one of 26 studies included patients with advanced 
CKD including those on RRT. However, it should be 
noted that there was no information available from low 
or middle- income countries. Mild to moderate CKD was 
also under- represented, despite this constituting 99% of 
the patients with CKD.46 Multimorbidity in patients with 
CKD from low and middle- income countries and in those 
with mild to moderate CKD should therefore be targets 
for future research. Only two studies assessed the influ-
ence of multimorbidity on cardiovascular outcomes.34 36 
Cardiovascular morbidity and mortality is the most signif-
icant risk for patients with CKD and many of the LTCs 
that occur in patients with CKD are risk factors for cardio-
vascular events.10 Further research is therefore needed 
to explore how multimorbidity influences cardiovascular 
events in patients with CKD. Of the four studies that exam-
ined the influence of multimorbidity on renal progres-
sion, all but one were in patients with renal transplants. 
The study in non- transplant patients identified an asso-
ciation between multimorbidity and renal progression.28 
This risk is a significant one, particularly for the patients 
who develop the need for RRT. Many patient cohorts 
around the world have ample follow- up data and so the 
influence of multimorbidity on renal progression in non- 
transplant cohorts should be studied in greater detail.
The studies included in our review are heterogeneous. 
Clinical heterogeneity is evident in the range of popu-
lations studied: stage 3 CKD, HD, PD, transplant and 
conservative care. There are high levels of methodolog-
ical and statistical heterogeneity. There is no consensus 
as to which multimorbidity measure should be used, and 
which measure is the most effective at predicting adverse 
outcomes.47 CCI was the most commonly used measure, 
although a number of modifications have been made for 
use in populations with CKD. Three studies included in 
this review compared different multimorbidity measures. 
CCI was found to effectively predict mortality risk, with 
other scoring systems performing comparably and none 
superior to the rest. Although our work demonstrates 
that various multimorbidity measures are associated with 
adverse clinical outcomes, we have not identified the best 
multimorbidity measure for risk prediction.
It has been recognised that there are fewer randomised 
controlled trials (RCTs) to assess the efficacy of interven-
tions in patients with CKD than in other medical special-
ties and that patients with CKD are often excluded from 
RCTs.48 49 Furthermore, patients with advanced CKD 
that are included in RCTs are not representative of the 
wider population of those with CKD.50 Similar observa-
tions have been made in other fields, whereby subjects 
with multimorbidity are under- represented in trials of 
novel interventions.51 Therefore, to improve outcomes 
for patients with CKD, both epidemiological studies and 
RCTs need to account for the range of multimorbidity 
in patients with CKD. A strength of our review is that it 
brings together information about the effects of multi-
morbidity in patients with CKD from various settings to 
create a comprehensive picture of the effects on different 
outcomes. Although the studies are challenging to 
summarise given the heterogeneity, the data are ample 
and clinically acceptable and therefore likely to be 
correct. Meta- analysis was performed with data from only 
10 studies. The data from 16 studies, including those with 
large sample sizes, therefore did not contribute to full 
data analysis. If a uniform multimorbidity measure were 
agreed and established in guidelines, the comparability 
and synthesis of data in future would be improved. The 
evaluation of the effects of types of LTCs on outcomes 
was limited because only two studies examined this issue. 
A key focus of future research should therefore be what 
patterns of multimorbidity or disease clusters exist in 
groups of patients with CKD.
In conclusion, this review provides evidence of asso-
ciations between multimorbidity and heightened risk 
of adverse clinical outcomes in patients with CKD. Our 
findings emphasise the need for further research into 
the details of how multimorbidity influences different 
outcomes. In particular, evidence gaps exist for patients 
with mild to moderate CKD, for outcomes other than 
mortality such as renal progression and cardiovascular 
events, for patients with CKD from low and middle- 
income countries and for the patterns of multimorbidity 
that contribute to heightened risk.
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